AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$QNRX

Lawlor Sally Bridget purchased $50K of QNRX

Lawlor Sally Bridget (Chief Financial Officer) purchased 10,244 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.

Original reporting
SEC EDGAR · Lawlor Sally Bridget
Published Sep 2, 2026, 1:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 1:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$QNRX
Neutral
high confidence
Mentioned
$QNRX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QNRXNeutralLow
01

Why it matters

The $50K buy is modest; investors may view it as a mild vote of confidence but it is unlikely to drive significant price movement.

02

Market read

Primary insider purchase with low materiality; limited trading relevance.

03

What to watch

CFO may be aligning compensation with upcoming milestones, which could affect future performance.

Relevance 4/10Novelty 7/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CFO's purchase.

Company-level read

Ticker impact

$QNRXNeutralHigh confidence
Context

CFO Lawlor Sally Bridget bought 10,244 shares for $49,990, a $50K insider purchase.

Expected impact

minimal price effect, likely flat to slight uptick.

Evidence & confidence

The transaction size is tiny relative to market cap; CFO involvement adds slight positive bias but not material.

Market effects

Sector

Negligible impact on the biotech sector; insider activity is routine.

Regional

No regional effect; limited to company-specific news.

Global

Insignificant for global markets.

Counterpoint

What could challenge this read

The purchase could be a signal of upcoming positive news not yet disclosed.

Key entities

  • Company
    Quoin Pharmaceuticals, Ltd.

    Biotech firm listed on Nasdaq under ticker QNRX.

  • Executive
    Lawlor Sally Bridget

    Chief Financial Officer of Quoin Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

QNRX insider trading history →

Related articles

SEP 8
$QNRXMedAI 8/10

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.

globenewswire.com2 min
AUG 28
$AEMDHighAI 8/10

Biotech Gainers: QNRX Leads Gains As AEMD, DWTX And FRNM Report Key Developments

Aethlon Medical (AEMD) reported a 12% narrower Q1 loss and progress in its Hemopurifier study, with shares up 17.5%. Quoin Pharmaceuticals (QNRX) surged 34% pre-market on positive QRX003 data and a $50M financing. Dogwood Therapeutics (DWTX) gained 12% as its Halneuron trial advances. Freenome (FRNM) rose 7% after FDA Breakthrough Device Designation for its lung cancer test.

rttnews.com3 min
AUG 28
$QNRXHighAI 9/10

Quoin Pharma Reports Positive Interim Data From Ongoing Phase 2/3 Study Of QRX003

Quoin Pharmaceuticals (QNRX) reported positive interim results from its Phase 2/3 study of QRX003 for Netherton Syndrome. Four of six patients showed significant improvement. The company expects to complete recruitment by the end of 2026 and report topline data in Q2 2027. If approved, QRX003 could be the first FDA-approved treatment for the condition. QNRX shares rose 55% to $7.99 in pre-market trading.

rttnews.com2 min
AUG 14
$QNRXMed

Quoin Pharmaceuticals, Ltd. (QNRX): Results of Operations and Financial Condition

Quoin Pharmaceuticals, Ltd. (QNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Com

SEC EDGAR 8-K6 min